Return to homepagePandemic Pact

Repurposing existing medications to reduce severe acute respiratory distress in patients with COVID-19: the CLARITY trial

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85491

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $970,545.03

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    UNSW Sydney

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The CLARITY trial will test whether a group of common blood pressure medications reduce the duration and severity of lung failure due to COVID-19. These medications have been in clinical use for over 30 years. They protect against lung injury in animal studies, including injury from viruses like the COVID-19 virus although the effect in humans is not known. Existing medications that lessen the severity of COVID-19 lung disease could provide some relief for patients and hospitals.